Novartis AG





Market Closed - Swiss Exchange 11:30:19 2024-07-23 EDT 5-day change 1st Jan Change
96.18 CHF -0.16% Intraday chart for Novartis AG -2.75% +13.33%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
DA Davidson Raises Price Target on Novartis to $120 From $110, Maintains Buy/Add Rating MT
Berenberg Raises Price Target on Novartis to CHF86 From CHF77, Maintains Hold Rating MT
NOVARTIS AG : Berenberg gives a Neutral rating ZD
Drug giants eye China for deals despite growing Sino-US tensions RE
Swiss Shares Start Major Week in the Green MT
EXECUTIVE CHANGES: NWF and Northern Bear pick new board chairs AN
Deutsche Bank Downgrades Novartis to Hold, Lifts PT MT
NOVARTIS AG : JP Morgan remains Neutral ZD
NOVARTIS : UBS raises its price target CF
NOVARTIS AG : DZ Bank maintains a Buy rating ZD
NOVARTIS AG : Deutsche Bank is now Neutral ZD
NOVARTIS AG : Goldman Sachs reaffirms its Buy rating ZD
NOVARTIS AG : UBS maintains a Buy rating ZD
Novartis CFO Warns Only-private Sale of New Prostate Cancer Drug Amid Questions on Pricing MT
Health Care Drops as Novo Nordisk, Eli Lilly Slide - Health Care Roundup DJ
Sector Update: Health Care Stocks Fall Thursday Afternoon MT
Swiss Market Index Closes in Red; ABB Slumps MT
Top Midday Stories: Taiwan Semiconductor, Novartis Shares Down Post-Earnings; Meta Weighs Bid for Ray-Ban Maker; Amazon Reports Record-Setting Prime Day MT
European Equities Close Mixed in Thursday Trading; European Central Bank Holds Rates Steady MT
Global markets live: ASML, Warner Bros, Beyond Meat, Meta, Alphabet... Our Logo
NOVARTIS : Q2 beat and another guidance upgrade Alphavalue
NOVARTIS AG : Bernstein maintains a Buy rating ZD
Exchange-Traded Funds Higher, Equity Futures Mixed Pre-Bell Thursday as Tech Stocks Recover MT
Transcript : Novartis AG, Q2 2024 Earnings Call, Jul 18, 2024
Trending : Novartis Raises Profit Guidance as It Prepares for Patent Expirations DJ
Chart Novartis AG
More charts
Logo Novartis AG
Novartis AG is one of the world's leaders in the design, manufacturing, and marketing of pharmaceutical products. Net sales (excluding discontinued operations) break down by therapeutic area as follows: - oncology (29.9%); - immunology (17.2%); - cardiovascular, renal and metabolic diseases (14.1%); - neuroscience (8.9%). The remaining net sales (29.9%) are from contract manufacturing of pharmaceutical products. At the end of 2023, Novartis AG had 33 production sites worldwide. Net sales are distributed geographically as follows: Europe (33%), the United States (39.5%), Asia/Africa/Australasia (20.5%), Canada and Latin America (7%).
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Mean consensus
Number of Analysts
Last Close Price
Average target price
Spread / Average Target
  1. Stock Market
  2. Equities
  3. NOVN Stock
  4. News Novartis AG
  5. Abu Dhabi, Novartis to Collaborate on Genomics Research for Cancer Therapy